Is UroGen Pharma a Stock to Sell After Its Chief Medical Officer Unloaded 5,222 Shares?
Written by Cory Renauer for The Motley Fool -> 5,222 shares were sold on June 8, 2026 for a transaction value of approximately $143,000 at a weighted average price around $27.30 per share. The transaction represented 3.60% of Mark Schoenberg's direct holdings, reducing his posi
5,222 shares were sold on June 8, 2026 for a transaction value of approximately $143,000 at a weighted average price around $27.30 per share.
The transaction represented 3.60% of Mark Schoenberg's direct holdings, reducing his position from 144,985 to 139,763 shares.
The activity was entirely direct; no indirect entities or trusts were involved, and the shares disposed came from an option exercise immediately preceding sale.
This sale follows a pattern of regular dispositions over the past year; trade sizes have moderated as direct share capacity has declined, with holdings now at approximately 62.5% of the September 2023 level.
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd. (NASDAQ:URGN) , reported the sale of 5,222 ordinary shares for a total of approximately $143,000, as disclosed in a SEC Form 4 filing .
Transaction value based on SEC Form 4 weighted average purchase price ($27.30); post-transaction value based on the value of post-transaction holdings as reported in the Form 4.
UroGen Pharma Ltd. operates as a biotechnology company focused on developing and commercializing innovative therapies for urinary tract cancers. The company leverages its proprietary RTGel platform and strategic partnerships to advance a pipeline of specialty oncology drugs targeting underserved patient populations.
With a strong emphasis on clinical development and commercialization, UroGen Pharma aims to address significant unmet medical needs in the urology and oncology sectors, positioning itself as a leader in the treatment of non-muscle invasive urothelial cancers.
